Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:20:05 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:CLNN from 2023-04-27 to 2024-04-26 - 29 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-16 16:01U:CLNNNews ReleaseEvidence for Clene's CNM-Au8(TM) as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
2024-03-19 08:30U:CLNNNews ReleaseIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
2024-03-15 08:00U:CLNNNews ReleaseClene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8(TM)
2024-03-13 08:00U:CLNNNews ReleaseClene Reports Full Year 2023 Financial Results and Recent Operating Highlights
2024-03-07 08:00U:CLNNNews ReleaseClene to Present at the 36th Annual ROTH Conference
2024-02-29 08:00U:CLNNNews ReleaseClene Presents Clinical Results of CNM-Au8(TM) 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
2024-02-22 08:00U:CLNNNews ReleaseClene Reports Significant Survival Benefit With CNM-Au8 ‚ ® Treatment in ALS EAP Compassionate Use Programs
2024-02-05 14:32U:CLNNNews ReleaseClene Inc. announces positive results from CNM-Au8 results from MS trial
2024-01-08 07:00U:CLNNNews ReleaseClene Reports Significant Improvement in Vision and Cognition With CNM-Au8 ‚ ® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
2023-12-21 07:00U:CLNNNews ReleaseClene Provides Update on ALS Clinical Development Meeting With FDA
2023-12-21 07:00U:CLNNNews ReleaseClene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8 ‚ ® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
2023-12-14 08:37U:CLNNNews ReleaseClene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
2023-11-07 08:00U:CLNNNews ReleaseClene Reports Third Quarter 2023 Financial Results and Operating Highlights
2023-10-05 10:00U:CLNNNews ReleaseNational Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 ‚ ® Study in ALS
2023-09-28 08:00U:CLNNNews ReleaseClene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
2023-09-25 16:00U:CLNNNews ReleaseClene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
2023-09-25 07:00U:CLNNNews ReleaseClene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
2023-08-30 08:20U:CLNNNews ReleaseClene to Present at Upcoming September Conferences
2023-08-29 07:00U:CLNNNews ReleaseClene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
2023-08-14 08:00U:CLNNNews ReleaseClene Reports Second Quarter 2023 Financial Results and Operating Highlights
2023-08-02 07:00U:CLNNNews ReleaseClene to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-06-26 08:00U:CLNNNews ReleaseClene Announces Publication of Phase 2 CNM-Au8 ‚ ® Clinical Data for the Treatment of ALS in LANCET ¢ € ™s eClinicalMedicine
2023-06-21 09:20U:CLNNNews ReleaseClene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
2023-06-16 08:00U:CLNNNews ReleaseClene Announces Pricing of $40 Million Public Offering
2023-06-15 16:39U:CLNNNews ReleaseClene Announces Launch of Proposed Public Offering
2023-06-15 16:29U:CLNNNews ReleaseClene ¢ € ™s CNM-Au8 ‚ ® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
2023-06-15 07:00U:CLNNNews ReleaseClene to Participate in the Maxim Group Virtual Healthcare Conference
2023-05-25 08:00U:CLNNNews ReleaseClene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8 ‚ ® in Non-Active Progressive Multiple Sclerosis
2023-05-12 16:00U:CLNNNews ReleaseClene Reports First Quarter 2023 Financial Results and Recent Operating Highlights